Zobrazeno 1 - 10
of 109
pro vyhledávání: '"L. L. Porter"'
Autor:
H, Choy, R F, DeVore, K R, Hande, L L, Porter, P, Rosenblatt, F, Yunus, L, Schlabach, C, Smith, Y, Shyr, K, LaPorte, D H, Johnson
Publikováno v:
Seminars in oncology. 24(4 Suppl 12)
We conducted a prospective phase II study to determine the response rate, toxicity profile, and survival rate among patients with locally advanced unresectable non-small cell lung cancer receiving concurrent weekly paclitaxel (Taxol; Bristol-Myers Sq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::44adb042787d5ab43867e252870229df
https://pubmed.ncbi.nlm.nih.gov/9331115
https://pubmed.ncbi.nlm.nih.gov/9331115
Autor:
T H, Grote, L F, Pineda, R A, Figlin, K B, Pendergrass, P J, Hesketh, B Y, Karlan, J A, Reeves, L L, Porter, C R, Benedict, W F, Hahne
Publikováno v:
The cancer journal from Scientific American. 3(1)
This double-blind, dose-response study was conducted to assess the safety and efficacy of four oral doses of dolasetron mesylate for preventing acute emesis in cancer patients receiving their first course of moderately emetogenic platinum-containing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d83eb57bb36988aaba64bbf439114623
https://pubmed.ncbi.nlm.nih.gov/9072308
https://pubmed.ncbi.nlm.nih.gov/9072308
Publikováno v:
Seminars in oncology. 23(1 Suppl 1)
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is an effective drug in the treatment of metastatic breast cancer (MBC). In the salvage setting, 5-fluorouracil (5-FU) and folinic acid have proved to be effective against MBC as well. R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d1b09036385b1ce0b117305304d73a05
https://pubmed.ncbi.nlm.nih.gov/8629038
https://pubmed.ncbi.nlm.nih.gov/8629038
Autor:
L. L. Porter, José Baselga, Ian Judson, Vassiliki A. Papadimitrakopoulou, Suzanne F. Jones, Katharine Hazell, S. Calvert, David Lebwohl, H. A. Burris, N. Shand
Publikováno v:
Journal of Clinical Oncology. 24:14599-14599
14599 Background: Activation of mammalian target of rapamycin (mTOR) is implicated in the pathogenesis of RCC. Hereditary RCC in tuberous sclerosis pts is associated with loss of function of TS complex genes and resultant activation of mTOR. In non-h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72d4c6ea7c96ff03e04496f068c2fba2
https://doi.org/10.1200/jco.2006.24.18_suppl.14599
https://doi.org/10.1200/jco.2006.24.18_suppl.14599
Publikováno v:
Plant Disease. 76:247
Powdery mildew, caused by Sphaerotheca pannosa var. rosae, and black spot,caused by Diplocarpon rosae, were significantly controlled by weekly sprays of 0.063 M aqueous solution of sodium bicarbonate plus 1.0% (v/v) Sunspray ultrafine spray oil on Ro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc60af67d80b80011cb4dc78ff584dcb
https://doi.org/10.1094/pd-76-0247
https://doi.org/10.1094/pd-76-0247
Publikováno v:
Journal of the Tennessee Medical Association. 73(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a74d40912d728ff04ca3d0178dc3e6ce
https://pubmed.ncbi.nlm.nih.gov/7382465
https://pubmed.ncbi.nlm.nih.gov/7382465
Publikováno v:
Seminars in oncology. 13(3 Suppl 3)
Small-cell lung cancer is rarely cured with standard chemotherapy, despite initial good responses. The concept of high-dose induction therapy for extensive-stage patients has been explained in a series of pilot studies. The rationale of this approach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a1b2027bb28f7eb7681df810e3145884
https://pubmed.ncbi.nlm.nih.gov/3020698
https://pubmed.ncbi.nlm.nih.gov/3020698
Publikováno v:
Cancer treatment reports. 69(5)
Twenty-nine patients with refractory recurrent small cell carcinoma of the lung were treated with cisplatin (40 mg/m2) and etoposide (200 mg/m2) each day for 3 days, repeated every 3-4 weeks. Fifteen of these patients had received etoposide in their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd31f465d514bcfa2d582ed6e3f82ef7
https://pubmed.ncbi.nlm.nih.gov/2988773
https://pubmed.ncbi.nlm.nih.gov/2988773
Autor:
J D, Hainsworth, L L, Porter, D H, Johnson, K R, Hande, S N, Wolff, R, Birch, G, Enas, F A, Greco
Publikováno v:
Cancer treatment reports. 70(3)
Ninety-two patients with advanced non-small cell lung cancer were treated with a combination chemotherapy regimen containing cisplatin, vindesine, and etoposide. Eighteen patients (20%) achieved major responses to therapy (three complete responders a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::13e08892375bd4d7860d3e72f785aab4
https://pubmed.ncbi.nlm.nih.gov/3955545
https://pubmed.ncbi.nlm.nih.gov/3955545
Publikováno v:
Seminars in oncology. 12(1 Suppl 2)
Etoposide (VP-16) is one of the most active drugs against small-cell lung cancer. There may be a steep dose-response relationship, and we have explored the use of etoposide as a single agent in a high dose (1,200 mg/m2) without bone marrow transplant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a7ca2a900887e1674385f6fa9f185dd0
https://pubmed.ncbi.nlm.nih.gov/2983434
https://pubmed.ncbi.nlm.nih.gov/2983434